Form 4: Cytokinetics EVP Buys Stock, Sells Options

Cytokinetics EVP of Research & Development, Fady Ibraham Malik, acquired 3,500 shares of common stock and sold 3,500 stock options.

Summary

• Fady Ibraham Malik, EVP of Research & Development at Cytokinetics Inc., reported a transaction on May 19, 2026.
• Malik acquired 3,500 shares of common stock at a price of $7.80 per share.
• Following this acquisition, Malik beneficially owns 157,402 shares of common stock directly.
• Concurrently, Malik disposed of 3,500 stock options for $75.69 per option.
• This transaction leaves Malik with 153,902 shares of common stock directly.
• A non-qualified stock option to buy common stock with an exercise price of $7.80 was also involved in the reporting, with 3,500 options acquired.
• These options were granted on March 27, 2018, and expire on February 27, 2028.
• Malik beneficially owns 47,886 derivative securities directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While the executive acquired stock, the disposal of options at a higher price is a standard financial maneuver rather than a strong indicator of future performance.

Positives

• Acquisition of 3,500 shares of common stock by a key executive, indicating confidence in the company.
• The executive's direct beneficial ownership of a significant number of shares (157,402) suggests alignment with shareholder interests.

Negatives

• Disposal of 3,500 stock options at a significantly higher price ($75.69) than the acquisition price of the common stock ($7.80), potentially indicating a realization of gains on previously granted options.

Future Outlook

The filing does not contain forward-looking statements or guidance. It reports on past transactions.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The acquisition of stock by an executive at a lower price than the disposal price of options suggests a strategic exercise and sale, common in executive compensation plans.

Stakeholder Impact

• Shareholders: The acquisition of stock by an executive may be viewed positively, suggesting confidence. However, the disposal of options is a standard compensation realization event.

Key Dates

Keywords

Cytokinetics, CYTK, Form 4, Insider Trading, Stock Options, Common Stock, Beneficial Ownership, SEC Filing, Executive Compensation